Search results
27 gru 2011 · These Kaplan-Meier curves illustrate overall survival (OS) for patients with rhabdoid tumor (ATRT). (A) The median OS for entire group was 10 months (n = 144). (B) The median OS for patients who presented with metastases was 3 months versus 13 months for those without metastases ( P = .0001).
Introduction. Atypical teratoid/rhabdoid tumor (AT/RT) is a highly aggressive embryonal CNS neoplasm, characterized by inactivation of SMARCB1 (INI1) or rarely of SMARCA4 (BRG1). While it is predominantly a childhood tumor, AT/RT is rare in adults. Methods.
Patients with AT/RT experienced worse outcomes compared to infants with tumors of other histologies, and the 5-year event free survival (EFS) and overall survival (OS) were 14% and 29%, respectively, which was not improved compared to historical controls.
6 paź 2020 · Atypical teratoid rhabdoid tumor (ATRT) is a rare, often lethal brain tumor of childhood characterized by a complex epigenetic landscape amongst a simple genetic background. Recent molecular studies have defined key biologic events that contribute to tumorigenesis and molecular subtypes of ATRT.
Atypical teratoid rhabdoid tumor (ATRT) is a rare, often lethal brain tumor of childhood characterized by a complex epigenetic landscape amongst a simple genetic background. Recent molecular studies have defined key biologic events that contribute to tumorigenesis and molecular subtypes of ATRT.
27 gru 2023 · When discussing survival rates, McGovern points to results from a recent clinical trial, which found that patients with ATRT treated with surgery followed by high-dose chemotherapy with stem cell rescue and focal radiation had overall survival rates of 43% and event-free survival rates of 37%.
Implementation of institutional multimodal approaches has remarkably improved the prognosis of selected cohorts of ATRT in 2-y and 5-year overall survival to almost 70%. 4, 56 It remains at 30–40% or less in unfavorable cohorts, including those with initial metastatic disease and age below 1 year. 4, 45, 57.
